Page last updated: 2024-08-05 12:22:35
fluoroindole
An organofluorine compound that is a compound based on an indole skeleton, containing one or more fluorine atoms.
ChEBI ID: 131960
Members (5)
| Member | Definition | Role |
|---|---|---|
| 5-fluoroindole | An organofluorine compound that is the 5-fluoro derivative of indole. | 5-fluoroindole |
| 680c91 | A fluoroindole that is 6-fluoroindole in which the hydrogen at position 3 has been replaced by a 2-(pyridin-3-yl)vinyl group (trans configuration). It is a selective inhibitor of tryptophan 2,3-dioxygenase (TDO), which directs the conversion of trypophan to kynurenin. | 680C91 |
| brivanib | A secondary alcohol resulting from the hydrolysis of the carboxylic ester group of brivanib alaninate. It is a dual VEGFR-2/FGFR-1 kinase inhibitor whose alanine prodrug, brivanib alaninate is currently under development as an oral agent for the treatment of cancer. | (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol; brivanib |
| l803087 | A fluoroindole that is 1H-indole substituted by phenyl, 4-{[(2S)-5-carbamimidamido-1-methoxy-1-oxopentan-2-yl]amino}-4-oxobutyl, fluoro and fluoro groups at positions 2, 3, 5 and 7, respectively. It is a selective nonpeptidic agonist of the somatostatin subtype-4 (SST4) receptor with Ki of 0.7 nM. | L-803087 |
| ly 367265 | A fluoroindole that is 1H-indole in which the hydrogens at positions 3 and 6 are replaced by 1-[2-(2,2-dioxo-5,6-dihydro-4H-2lambda(6)-[1,2,5]thiadiazolo[4,3,2-ij]quinolin-1(2H)-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl and fluoro groups, respectively. It is an inhibitor of the 5-hydroxytryptamine transporter (Ki = 2.3 nM) and an antagonist of 5-hydroxytryptamine(2A) receptor (Ki = 0.81 nM). | LY-367,265 |
Research
Studies (135)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.22) | 18.2507 |
| 2000's | 27 (20.00) | 29.6817 |
| 2010's | 91 (67.41) | 24.3611 |
| 2020's | 14 (10.37) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 19 (13.10%) | 5.53% |
| Reviews | 12 (8.28%) | 6.00% |
| Case Studies | 3 (2.07%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 111 (76.55%) | 84.16% |